GlassScriptPhysician profile
Lori A Robbins
NPI 1629417761
$8,934.40
in general payments reported to CMS, 2019-2025
36 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.73 · 2020: $455 · 2021: $1,070 · 2022: $1,526 · 2023: $1,384 · 2024: $2,147 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,796 · Education: $30.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,795.84 |
| Education | $30.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,437.09 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $880.51 | 2020-2025 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $620.77 | 2021-2025 | Tremfya, Stelara, Remicade |
| Qol Medical, LLC | $534.06 | 2020-2025 | Sucraid, Sucraid |
| Celgene Corporation | $523.36 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $397.58 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $305.86 | 2020-2025 | |
| Pfizer INC. | $301.29 | 2021-2025 | |
| Genzyme Corporation | $270.73 | 2022-2025 | |
| Lilly USA, LLC | $256.30 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $246.71 | 2020-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $244.86 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $223.81 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $215.58 | 2019-2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $214.37 | 2021-2025 | Entyvio, Eohilia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $202.83 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $171.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $166.08 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $93.13 | 2021-2023 | |
| Celltrion USA INC. | $72.96 | 2024-2025 | Vegzelma, Zymfentra |
| Organon LLC | $71.25 | 2023-2024 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $65.91 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $55.75 | 2025 | Wegovy |
| Amgen INC. | $51.61 | 2021-2023 | Avsola, Amjevita |
| Axonics, INC. | $47.63 | 2022-2024 | Axonics |
| Alnylam Pharmaceuticals INC. | $44.78 | 2024-2025 | Givlaari |
| Boston Scientific Corporation | $43.53 | 2021-2025 | Axonics |
| Neuraxis, INC. | $39.94 | 2025 | |
| Alfasigma USA, INC. | $23.11 | 2020 | |
| Enterra Medical, INC. | $22.12 | 2023 | |
| Lucid Diagnostics INC. | $19.78 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.01 | 2021 | |
| Pharmacosmos Therapeutics INC. | $14.90 | 2021 | |
| Daiichi Sankyo INC. | $13.57 | 2020 | |
| Azurity Pharmaceuticals, INC. | $13.57 | 2025 | Sutab |
| Allergan, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.